Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer

Background: Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing evidence indicates that treatment efficacy, and toxicity varies considerably between individuals. Therefore, this study aimed to investigate the relationship between cytochrome P450 (CYP450) gene polymorphi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Tingfei, Han, Gongwei, Cheng, Ziwei, Jiang, Jiemei, Zhang, Li, Xia, Zitong, Wang, Xinmeng, Xia, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257029/
https://www.ncbi.nlm.nih.gov/pubmed/35814206
http://dx.doi.org/10.3389/fphar.2022.918219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257029/
https://www.ncbi.nlm.nih.gov/pubmed/35814206
http://dx.doi.org/10.3389/fphar.2022.918219

Ejemplares similares